Charles River Laboratories (CRL) Tops Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $345.37 +1.68%
EPS Growth %: +22.2%
Financial Fact:
Other, net: 1.02M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +22.2%
Financial Fact:
Other, net: 1.02M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.40, $0.15 better than the analyst estimate of $1.25. Revenue for the quarter came in at $478.5 million versus the consensus estimate of $474.59 million.
GUIDANCE:
Charles River Laboratories sees FY2018 EPS of $5.42-$5.57, versus the consensus of $5.58.
- Revenue growth, reported 7.2% - 8.2%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Investing.com’s stocks of the week
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
